Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 85 | |||||
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 93 | 72 | 63 | 41 | 35 | 29 | 35 | 157 | 175 | 195 | 121 | 35 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | 3 | 1 | |||||
Other Assets Current | - | - | - | - | - | - | - | - | - | - | 0 | 2 | |||||
Assets Current | |||||||||||||||||
Assets Current | 218 | 201 | 188 | 128 | 140 | 105 | 126 | 159 | 177 | 198 | 124 | 39 | |||||
Short Term Investments | - | - | - | - | - | 71 | 87 | - | - | - | - | - | |||||
Available For Sale Securities Debt Securities Curr… | 119 | 121 | 119 | 82 | 97 | - | 87 | - | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 6 | 8 | 7 | 5 | 7 | 5 | 5 | 2 | 2 | 3 | 3 | - | |||||
Available For Sale Securities Debt Securities Nonc… | 22 | 35 | 65 | 0 | 20 | - | 7 | - | - | - | - | - | |||||
Equity Securities F V N I Noncurrent | 3 | 3 | 3 | 3 | 3 | - | 0 | - | - | - | - | - | |||||
Restricted Cash Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Long Term Investments | - | - | - | - | - | 7 | 7 | - | - | - | - | - | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Finance Lease Right Of Use Asset | - | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | |||||
Operating Lease Right Of Use Asset | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | |||||
Assets | 255 | 250 | 269 | 144 | 176 | 126 | 147 | 174 | 192 | 213 | 140 | 55 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 4 | 3 | 5 | 5 | 20 | 12 | 6 | 8 | 6 | 4 | 4 | 3 | |||||
Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Accrued Bonuses Current | - | - | - | - | - | - | - | - | - | 1 | 3 | 2 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 16 | 14 | 17 | 17 | 32 | 31 | 23 | 27 | 19 | 22 | 17 | 23 | |||||
Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 4 | |||||
Finance Lease Liability Current | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Liabilities Noncurrent | |||||||||||||||||
Finance Lease Liability Noncurrent | - | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Liability Noncurrent | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | |||||
Liabilities | 20 | 19 | 22 | 23 | 38 | 38 | 30 | 35 | 27 | 30 | 26 | 32 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | - | - | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital Common Stock | 662 | 632 | 627 | 480 | 477 | 401 | 397 | 394 | 390 | 386 | 295 | 5 | |||||
Stockholders Equity | 235 | 231 | 247 | 121 | 138 | 88 | 117 | 139 | 165 | 183 | 114 | -163 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | -0 | 0 | 0 | -0 | -0 | -0 | - | - | - | - | - | |||||
Retained Earnings Accumulated Deficit | -426 | -400 | -380 | -359 | -339 | -313 | -280 | -254 | -225 | -204 | -182 | -168 | |||||
Liabilities And Stockholders Equity | 255 | 250 | 269 | 144 | 176 | 126 | 147 | 174 | 192 | 213 | 140 | 55 | |||||
Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 144 | |||||
Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 144 | |||||
Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 144 | |||||
Temporary Equity Liquidation Preference | - | - | - | - | - | - | - | - | - | - | - | 186 | |||||
Series B Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 58 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 18 | |||||
Common Stock Shares Issued | 79 | 74 | 73 | 55 | 54 | 33 | 33 | 33 | 33 | 33 | 27 | 2 | |||||
Shares Outstanding | 79 | 74 | 73 | 55 | 54 | 33 | 33 | 33 | 33 | 33 | 27 | 2 | |||||
Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -28.59% | -23.37% | -28.92% | - | - | - | - | - | - | - | - | - |
| 2025 | 47.53% | 69.20% | 75.29% | 4.80% | 38.20% | 108.98% | 20.24% | 25.00% | -8.54% | 11.01% | -3.04% | -6.45% |
| 2024 | 14.69% | 10.62% | -20.69% | -9.02% | -27.71% | -33.81% | -0.13% | -4.58% | -28.93% | -33.74% | -20.78% | -3.67% |
| 2023 | - | - | - | - | - | - | 43.51% | 68.48% | 47.37% | -10.35% | -11.87% | 14.77% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Lexeo Therapeutics, Inc. (LXEO) — SEC Financial Statements & Analysis
Lexeo Therapeutics, Inc. (LXEO) is a biological products, (no diagnostic substances) company. Lexeo Therapeutics, Inc. trades on Nasdaq as: LXEO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Lexeo Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.08x, a Price-to-Book (P/B) ratio of 1.70x (TTM), at a market cap of $398.59M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.08x
- P/B TTM
- 1.70x
- Market Cap
- $398.59M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lexeo Therapeutics, Inc. in?
Lexeo Therapeutics, Inc. (LXEO) operates in the Biological Products, (No Diagnostic Substances) industry.
What is LXEO's market cap?
Lexeo Therapeutics, Inc. (LXEO) has a market capitalization of $398.59M as of 2026-06-30.
What exchange does LXEO trade on?
Lexeo Therapeutics, Inc. (LXEO) trades on the Nasdaq.